Morgan Stanley sets USD 115 target for BioNTech stock

BioNTech SE (ISIN US09075V1026) was trading at EUR 86.70 at Lang & Schwarz on October 2, 2026 at 4:12 p.m. CEST, plus 0.64 percent versus the prior close of EUR 86.15. On September 21, 2026, Morgan Stanley analyst Terence Flynn maintained a Buy rating and set a USD 115.00 price target, as Markets Insider reported.

Oncology data sharpen the story

BioNTech and OncoC4 reported updated gotistobart data on September 14, 2026. Median overall survival reached 18.50 months with gotistobart versus 10.00 months with standard-of-care chemotherapy in stage 1 of the PRESERVE-003 Phase 3 trial, according to FinanzNachrichten. The comparison gives investors a concrete measure of the drug candidate's clinical signal, while the ongoing pivotal stage remains the next test.

The same update identified 87 randomized patients at the July 17, 2026 data cutoff, with 45 receiving gotistobart and 42 receiving docetaxel. Treatment-related adverse events of grade 3 or higher affected 44.40 percent of the gotistobart group and 48.80 percent of the chemotherapy group, the company release carried by FinanzNachrichten reported.

Losses keep the valuation debate open

BioNTech's second-quarter revenue was USD 105.60 million, down from USD 260.80 million in the year-earlier quarter, while its GAAP net loss widened to USD 820.80 million from USD 386.60 million, according to Markets Insider. The earnings contrast puts greater weight on pipeline execution and upcoming clinical milestones than on current commercial revenue.

Analyst views remain divided on the timing of that transition. UBS kept a Buy rating and a USD 135.00 target on September 16, 2026, according to MarketScreener, while Goldman Sachs cut its target from USD 128.00 to USD 127.00 and retained Buy on September 4, 2026, as FinanzNachrichten reported.

November results set the next test

BioNTech is scheduled to release third-quarter 2026 results on November 2, 2026, according to MarketScreener. That report will give investors a fresh read on cash resources, research spending and the pace at which oncology programs can offset weaker product revenue.

Stock holds above the prior close

BioNTech stock was trading at EUR 86.70 at Lang & Schwarz on October 2, 2026 at 4:12 p.m. CEST, up EUR 0.55 or 0.64 percent versus the EUR 86.15 prior close dated October 1, 2026. The finance quote showed a USD 24.4 billion market capitalization and a USD 79.52 to USD 124.00 52-week range on October 2, 2026.

The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.

More news and analyses on BioNTech stock